

January 08, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 532372

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex, Bandra
(E), Mumbai - 400 051
Symbol: VIRINCHI

Dear Sir/Madam,

Subject : Allotment of Convertible Equity Warrants
Reference : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that consequent to the special resolution passed by the shareholders of the Company at an Extra-Ordinary General Meeting convened on Saturday, November 15, 2025 for issuance of 2,00,00,000(Two Crore only) convertible equity warrants and pursuant to the in-principle approval given by BSE vide their letter LOD/PREF/KS/FIP/1456/2025-26 dated December 31, 2025; and by NSE vide their letter NSE/LIST/51564 dated December 31, 2025, the Stakeholders Relationship Committee at its meeting held today i.e. Thursday, January 08, 2026 has approved the allotment of 86,00,000 (Eighty Six Lakh only) convertible equity warrants at an Issue Price of Rs.28/- (Face Value of Rs.10/- and Premium of Rs.18/-) on preferential basis in accordance with SEBI (ICDR) Regulations, 2018, to the following persons on receipt of the subscription amount equivalent to 25% of the Issue Price:

S.No	Name of Allotees	Category	No. of Warrants Allotted
1	Vivo Bio Tech Limited	Promoter Group	86,00,000
TOTAL			86,00,000

We would further like to state that fully paid-up equity shares of face value of Rs. 10/- each of the Company against each Warrant shall be allotted on receipt of balance 75% of the issue price for each Warrant.

Warrants have been allotted upon receipt of 25% of the total consideration (i.e receipt of Rs. 7/- per warrant - out of the total of Rs. 28/- per warrant) and are convertible into equal number of equity shares upon receipt of the balance amount i.e., Rs. 21/- per warrant, within the stipulated time.

Pursuant to above allotment of Warrants, presently there is no change in the paid-up share capital of the Company.

The details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as **Annexure I**.

This is for your information and records.

Thanking you,

Yours faithfully,

For Virinchi Limited

K Ravindranath Tagore
Company Secretary

Encl. as above

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 ("Master Circular").

S.No.	Particulars	Disclosure																																
1.	Type of securities proposed to be Issued	Fully Convertible Equity Warrants ("Warrants")																																
2.	Type of issuance	Preferential Issue																																
3.	Outcome of the Subscription, type of issue, type of securities and total number of securities	The following are details of outcome of subscription: <table border="1"> <thead> <tr> <th>Type of issue</th> <th>Type of Securities</th> <th>Issued</th> <th>Subscribed and allotted</th> </tr> </thead> <tbody> <tr> <td>Preferential</td> <td>Convertible Equity Warrants</td> <td>2,00,00,000</td> <td>86,00,000</td> </tr> </tbody> </table> 86,00,000 (Eighty Six Lakh only) convertible equity warrants allotted at an Issue Price of Rs.28/- (Face Value of Rs.10/- and Premium of Rs.18/-) on receipt of 25% subscription amount aggregating to Rs. 6,02,00,000/- (Rupees Six Crore Two Lakh only).				Type of issue	Type of Securities	Issued	Subscribed and allotted	Preferential	Convertible Equity Warrants	2,00,00,000	86,00,000																					
Type of issue	Type of Securities	Issued	Subscribed and allotted																															
Preferential	Convertible Equity Warrants	2,00,00,000	86,00,000																															
4.	Name and number of the Investor(s)	<table border="1"> <thead> <tr> <th>S.No.</th> <th>Names of the Allottees</th> <th>Category</th> <th>No. of Warrants</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Vivo Bio Tech Limited</td> <td>Promoter Group</td> <td>86,00,000</td> </tr> <tr> <td></td> <td></td> <td>Total</td> <td>86,00,000</td> </tr> </tbody> </table>				S.No.	Names of the Allottees	Category	No. of Warrants	1.	Vivo Bio Tech Limited	Promoter Group	86,00,000			Total	86,00,000																	
S.No.	Names of the Allottees	Category	No. of Warrants																															
1.	Vivo Bio Tech Limited	Promoter Group	86,00,000																															
		Total	86,00,000																															
5.	Post allotment of securities - outcome of the subscription.	<table border="1"> <thead> <tr> <th rowspan="2">Category</th> <th colspan="2">Pre preferential issue</th> <th colspan="2">Post preferential issue*</th> </tr> <tr> <th>No of Shares</th> <th>%</th> <th>No of Shares</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Promoters and Promoter Group (A)</td> <td>3,85,05,538</td> <td>37.51</td> <td>4,71,05,538</td> <td>42.34</td> </tr> <tr> <td>Public (B)</td> <td>6,41,41,358</td> <td>62.49</td> <td>6,41,41,358</td> <td>57.66</td> </tr> <tr> <td>Non-Promoter-Non Public Shareholding (C)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Total (A) + (B)+(C)</td> <td>10,26,46,896</td> <td>100</td> <td>11,12,46,896</td> <td>100</td> </tr> </tbody> </table> <p>* The above post-issue shareholding is prepared assuming conversion of Warrants (allotted) into equity shares, pursuant to this preferential issue.</p>				Category	Pre preferential issue		Post preferential issue*		No of Shares	%	No of Shares	%	Promoters and Promoter Group (A)	3,85,05,538	37.51	4,71,05,538	42.34	Public (B)	6,41,41,358	62.49	6,41,41,358	57.66	Non-Promoter-Non Public Shareholding (C)	0	0	0	0	Total (A) + (B)+(C)	10,26,46,896	100	11,12,46,896	100
Category	Pre preferential issue		Post preferential issue*																															
	No of Shares	%	No of Shares	%																														
Promoters and Promoter Group (A)	3,85,05,538	37.51	4,71,05,538	42.34																														
Public (B)	6,41,41,358	62.49	6,41,41,358	57.66																														
Non-Promoter-Non Public Shareholding (C)	0	0	0	0																														
Total (A) + (B)+(C)	10,26,46,896	100	11,12,46,896	100																														
6.	Intimation on conversion of securities or on lapse of the tenure	The tenure of the Warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant would be convertible into 1 Equity Share and the rights attached to Warrants can be exercised in one or more tranches, within 18 (eighteen months) from the date of																																

	of the instrument	allotment of such warrants. In the event that a Warrant holder does not exercise the Warrants within a period of 18 (eighteen) months from the date of allotment of such warrants, the unexercised Warrants shall lapse and the amount paid by that Warrant holder on such Warrants shall stand forfeited by the Company.
7.	Nature of Consideration	Cash
8.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable